Organic Chemical – Page 4

Biogen Ushers Spinraza Follow-Up (Salanersen) Into Pivotal SMA Studies

1 month ago talkbio0Tagged Antistreptolysin O, Biogen, Clinical Trials, motor milestones, Nerve Degeneration, Novartis, Pediatric brand name, Phase III, salanersen, Spinal Muscular Atrophy, Spinraza, Zolgensma

Biogen; SMA; Spinraza; salanersen; Phase III; clinical trials; neurodegeneration; motor milestones; pediatric; Novartis Zolgensma; ASO therapy

Sanofi Licenses Formation Bio’s JAK/SYK Inhibitor Gusacitinib in $630M+ AI-Driven Deal

1 month ago talkbio0Tagged AI drug development, Anabolism, Bio, chronic hand eczema, gusacitinib, Indication of (contextual qualifier), JAK/SYK inhibitor, Libertas Bio, licensing agreement, sanofi

Sanofi; Formation Bio; gusacitinib; JAK/SYK inhibitor; AI drug development; Libertas Bio; deal; chronic hand eczema; new indication; licensing agreement

Exelixis’ Zanzalintinib Achieves Key Survival Goal in Pivotal Colorectal Cancer Study

1 month ago talkbio0Tagged atezolizumab, checkpoint inhibitor, Clinical Trials, Colorectal Carcinoma, Exelixis, Overall Survival, STELLAR-303, Stivarga, zanzalintinib

Exelixis; zanzalintinib; colorectal cancer; pivotal trial; overall survival; atezolizumab; checkpoint inhibitor; Stivarga; STELLAR-303; clinical trial

Exelixis’ Phase 3 Colorectal Cancer Data Sends Stock Higher

1 month ago talkbio0Tagged Clinical Trials, Colorectal Carcinoma, Exelixis, regorafenib, STELLAR-303, surge, Tecentriq, zanzalintinib

Exelixis; zanzalintinib; colorectal cancer; Phase 3 trial; STELLAR-303; Tecentriq; Regorafenib; clinical trial results; stock surge

Compass Pathways Achieves Phase 3 Win for Psilocybin in Depression, Yet Stock Tumbles

1 month ago talkbio0Tagged Clinical Trials, COMP360, Compass Pathways, Investor Reaction, Mental Depression, Psilocybin, Stock Decline, treatment-resistant depression, United States Food and Drug Administration

Compass Pathways; COMP360; psilocybin; Phase 3 trial; depression; treatment-resistant depression; clinical trial; stock decline; investor reaction; FDA

Gilead Wins Groundbreaking FDA Approval for Twice-Yearly HIV Prevention Shot

1 month ago talkbio0Tagged Approved, Gilead, Guidelines, HIV Prevention, Lenacapavir, Long-acting injectable, PREP gene, twice-yearly injection, United States Food and Drug Administration, World Health Organization, Yeztugo

Gilead; FDA approval; lenacapavir; Yeztugo; HIV prevention; twice-yearly injection; PrEP; long-acting injectable; WHO guidelines

FDA Approves Gilead’s Twice-Yearly HIV Prevention Shot

1 month ago talkbio0Tagged Approved, Gilead Sciences, HIV Prevention, Lenacapavir, PREP gene, public health medicine (field), twice-yearly injection, United States Food and Drug Administration, Yeztugo

FDA approval; Gilead Sciences; Lenacapavir; Yeztugo; HIV prevention; twice-yearly injection; PrEP; public health

Trump Administration Considers Limits on Direct-to-Consumer Drug Advertising

1 month ago talkbio0Tagged Ditiocarb, drug price, executive order, Health Policy, Pharma, pharmaceutical regulation, Transplant Registry Unified Management Program

Trump administration; DTC drug advertising; pharmaceutical regulation; drug pricing; executive order; health policy; pharma marketing

IPG Health Leads at Cannes Lions 2025 as Real Chemistry and Ogilvy Health Earn Major Awards

1 month ago talkbio0Tagged Agencies, Cannes, Geographic Locations, Grand Prix, Health, Health & Wellness, Health Care Market, IPG, Ogilvy Health, Science of Chemistry, Vaseline, Verification

Cannes Lions 2025; IPG Health; Real Chemistry; Ogilvy Health; healthcare marketing; agency awards; Health & Wellness Lions; Grand Prix; AREA 23; Vaseline Verified

Roche and AbbVie Announce Phase 3 Venclexta Trial Fails to Meet Primary Endpoint in High-Risk MDS

1 month ago talkbio0Tagged AbbVie, Antineoplastic Agents, azacitidine, Clinical Research, Clinical Trials, Miller Dieker syndrome, MYELODYSPLASTIC SYNDROME, Phase 3 trial, Roche (company), Venclexta, venetoclax, Verona

Roche; AbbVie; Venclexta; venetoclax; azacitidine; myelodysplastic syndromes; MDS; Phase 3 trial; VERONA study; clinical trial results; cancer drug